人源生物工程无细胞血管用于外周动脉疾病动脉重建的首次人体研究
本研究将人源生物工程无细胞血管(HAV)植入20例外周动脉疾病患者,作为膝上股-腘动脉旁路 conduit。2年随访显示HAV安全、通畅率可接受、感染率低,无需采集自体静脉或细胞,组织学证实血管重塑和宿主细胞再填充。
要点
- HAV可即取即用于外周动脉旁路,无需自体静脉或细胞采集。
- 20例膝上股-腘旁路2年随访无结构失败或排斥,无HAV感染。
- 组织学显示HAV植入后发生血管重塑和宿主细胞再填充。
核心结论
- 人源组织工程血管可制造并随时用于外周动脉旁路手术。
- 早期临床经验提示HAV在动脉位置安全、通畅率可接受、感染率低,且无需采集自体静脉或受体细胞。
研究设计与样本
- 首次人体临床研究,纳入20例有症状外周动脉疾病患者。
- HAV由人血管平滑肌细胞在可降解支架上生长,后脱细胞去除人细胞抗原。
- HAV植入为膝上股-腘动脉旁路 conduit,随访2年评估安全性、耐久性、无感染和通畅率。
主要发现
- 20例中静息痛3例,有症状跛行17例。
- 所有HAV按预期功能运行,无结构失败或受体排斥证据。
- 研究期间无急性HAV感染,但记录3例手术部位感染。
- 报告3例非HAV相关死亡。
- 1例血管在球囊血栓切除术后疑似医源性损伤后出现假性动脉瘤。
关键数值与推荐
- 20例HAV植入膝上股-腘动脉位置,随访2年。
- 无HAV感染报告约34患者年连续随访。
临床怎么用
- HAV可作为外周动脉旁路手术的现成血管 conduit,避免自体静脉采集。
- 术后需监测手术部位感染和医源性损伤相关并发症如假性动脉瘤。
局限性
- 首次人体研究,样本量20例,随访2年。
- 原文未报告通畅率具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Vascular conduit is essential for arterial reconstruction for a number of conditions, including trauma and atherosclerotic occlusive disease. We have developed a tissue-engineered human acellular vessel (HAV) that can be manufactured, stored on site at hospitals, and be immediately available for arterial vascular reconstruction. Although the HAV is acellular when implanted, extensive preclinical and clinical testing has demonstrated that the HAV subsequently repopulates with the recipient's own vascular cells. We report a first-in-man clinical experience using the HAV for arterial reconstruction in patients with symptomatic peripheral arterial disease. METHODS: HAVs were manufactured using human vascular smooth muscle cells grown on a biodegradable scaffold. After the establishment of adequate cell growth and extracellular matrix deposition, the vessels were decellularized to remove human cellular antigens. Manufactured vessels were implanted in 20 patients with symptomatic peripheral arterial disease as above-knee, femoral-to-popliteal arterial bypass conduits. After HAV implantation, all patients were assessed for safety, HAV durability, freedom from conduit infection, and bypass patency for 2 years. RESULTS: Twenty HAVs were placed in the arterial, above-knee, femoral-to-popliteal position in patients with rest pain (n = 3) or symptomatic claudication (n = 17). All HAVs functioned as intended and had no evidence of structural failure or rejection by the recipient. No acute HAV infections were reported, but three surgical site infections were documented during the study period. Three non-HAV-related deaths were reported. One vessel developed a pseudoaneurysm after suspected iatrogenic injury during a balloon thrombectomy. No amputations of the HAV implanted limb occurred over the 2-year period, and no HAV infections were reported in approximately 34 patient-years of continuous patient follow-up. CONCLUSIONS: Human tissue engineered blood vessels can be manufactured and readily available for peripheral arterial bypass surgery. Early clinical experience with these vessels, in the arterial position, suggest that they are safe, have acceptable patency, a low incidence of infection, and do not require the harvest of autologous vein or any cells from the recipient. Histologic examination of tissue biopsies revealed vascular remodeling and repopulation by host cells. This first-in-man arterial bypass study supports the continued development of human tissue engineered blood vessels for arterial reconstruction, and potential future expansion to clinical indications including vascular trauma and repair of other size-appropriate peripheral arteries.
引用
- Gutowski P, Gage SM, Guziewicz M, et al. Arterial reconstruction with human bioengineered acellular blood vessels in patients with peripheral arterial disease. J Vasc Surg. 2020. PMID: 32093913. doi:10.1016/j.jvs.2019.11.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。